NCT01756079View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 6, 2013

Primary Completion Date

November 17, 2015

Study Completion Date

November 17, 2015

Conditions
Hepatitis C
Interventions
DRUG

boceprevir

BIOLOGICAL

PegIFN-2b

DRUG

RBV

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01756079 - A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105) | Biotech Hunter | Biotech Hunter